Human Anti-HIV-1 gp41 Recombinant Antibody (clone 4E10) (CAT#: PABL-192)

Recombinant Human Antibody (4E10) is capable of binding to HIV-1 gp41 transmembrane subunit, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp41 transmembrane subunit mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 gp41 transmembrane subunit mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This broadly neutralizing antibody could interact with membrane lipids, but the antibody regions contacting lipids and its orientation with respect to the viral membrane are unknown.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Neutralizing activity of MPER-specific IgA1 on primary and laboratory HIV-1 strains. 4E10 and 2F5 were used as positive controls. Dose-dependent neutralization was performed within a concentration range of 0.156–10 mg/ml.

Figure 1 Neutralizing activity of MPER-specific IgA1 on primary and laboratory HIV-1 strains. 4E10 and 2F5 were used as positive controls. Dose-dependent neutralization was performed within a concentration range of 0.156–10 mg/ml.

Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.

Figure 2 Binding of MPER-specific IgA on SupT1/LAI-infected cells. Number of IgA+/p24+ SupT1 cells was analyzed by flow cytometry. 4E10 was used as positive control and labeling with anti-p24+ + anti-IgA-PE as negative control. The ratio of the mean fluorescence of IgA+/p24+ SupT1 cells on the mean fluorescence of IgA2/p24+ SupT1 cells is indicated. Uninfected cells were used as negative control.

Figure 2 Binding of MPER-specific IgA on SupT1/LAI-infected cells. Number of IgA+/p24+ SupT1 cells was analyzed by flow cytometry. 4E10 was used as positive control and labeling with anti-p24+ + anti-IgA-PE as negative control. The ratio of the mean fluorescence of IgA+/p24+ SupT1 cells on the mean fluorescence of IgA2/p24+ SupT1 cells is indicated. Uninfected cells were used as negative control.

Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.

Figure 3 Competition assay for C6.11 and F4.30 binding to gp120c41 in the presence of 2F5 or 4E10. gp120c41-coated wells were preincubated with 2F5 or 4E10 at different concentrations (0–20 mg/ml). C6.11 and F4.30 were used at 5 mg/ml. Assays were performed in triplicate.

Figure 3 Competition assay for C6.11 and F4.30 binding to gp120c41 in the presence of 2F5 or 4E10. gp120c41-coated wells were preincubated with 2F5 or 4E10 at different concentrations (0–20 mg/ml). C6.11 and F4.30 were used at 5 mg/ml. Assays were performed in triplicate.

Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.

Figure 4 Kinetic analysis of the interaction between MPER-specific IgA and recombinant gp120c41. C6.11 (5–80 nM), F4.30 (0.5–16 nM), and 4E10 (0.5–8 nM) were injected over 8200 RU of immobilized gp120c41 in PBS containing 0.005% surfactant P20.

Figure 4 Kinetic analysis of the interaction between MPER-specific IgA and recombinant gp120c41. C6.11 (5–80 nM), F4.30 (0.5–16 nM), and 4E10 (0.5–8 nM) were injected over 8200 RU of immobilized gp120c41 in PBS containing 0.005% surfactant P20.

The binding signals shown were obtained by double referencing (subtraction of the reference surface and of buffer blank injection signals). Fits are shown as dotted lines and were obtained by global fitting of the data using a 1:1 Langmuir binding model.

Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.

Figure 5 Screening of the neutralizing activity of MPER-specific IgA on COT6.15 pseudoviruses and COT6.15 mutants.

Figure 5 Screening of the neutralizing activity of MPER-specific IgA on COT6.15 pseudoviruses and COT6.15 mutants.

MPER sequence is shown in each panel. For each mAb and mutant, the value of SD is calculated for the neutralization from two independent experiments realized in triplicate. The critical residues for neutralization are indicated in red.

Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.

Figure 6 Interactions of 10E8 with lipid bilayers.

Figure 6 Interactions of 10E8 with lipid bilayers.

A liposome flotation assay was used to detect binding to HIV-1-like membranes at 37°C by various antibodies, i.e., 17b, 4E10, 10E8, 10E8-F100aA, and 10E8-W100bA. Seven fractions throughout the sucrose gradient (from top [t] to bottom) after centrifugation were collected and analyzed by Western blotting. The heavy and light chains of antibodies are indicated by H and L, respectively.

Chen, J., Frey, G., Peng, H., Rits-Volloch, S., Garrity, J., Seaman, M. S., & Chen, B. (2014). Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. Journal of virology, 88(2), 1249-1258.


Specifications

  • Host Species
  • Human
  • Type
  • Human IgG
  • Species Reactivity
  • HIV-1
  • Clone
  • 4E10
  • Applications
  • WB, Neut, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for Neut, FC, ELISA and WB. For details, refer to published data.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160; precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 4E10"

See other products for "HIV-1 gp41"

MHC Tetramer for Virology

CAT Product Name Application Type
MHC-LC746 A*2402/HIV-1 gp41 (RYLKDQQLL) MHC Tetramer FCM

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-192. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare